Extracted from this filing and checked against the source text.
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Immunome Inc. entered into Stock Issuance Agreement with Zentalis Pharmaceuticals, Inc. (effective 2024-01-05).
- Action
- entry
- Agreement
- license
- Counterparty
- Zentalis Pharmaceuticals, Inc.
- Effective
- 2024-01-05
Exact text from the filing
Concurrently with the execution of the License Agreement, the Company entered into a stock issuance agreement (the “Stock Issuance Agreement”) with Zentalis, pursuant to which the Company issued 2,298,586 shares of the Company’s common stock (the “Shares”), as partial consideration for the rights licensed to the Company from Zentalis pursuant to the License Agreement.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Immunome Inc. entered into License Agreement with Zentalis Pharmaceuticals, Inc. valued at $35 million (effective 2024-01-05).
- Action
- entry
- Agreement
- license
- Counterparty
- Zentalis Pharmaceuticals, Inc.
- Value
- $35 million
- Effective
- 2024-01-05
Exact text from the filing
On January 5, 2024, Immunome, Inc. (the “Company”) entered into a license agreement (“License Agreement”) with Zentalis Pharmaceuticals, Inc. (“Zentalis”), pursuant to which the Company received an exclusive, worldwide, royalty-bearing, sublicensable license under certain intellectual property relating to Zentalis’ proprietary antibody-drug conjugate (“ADC”) platform technology, ROR1 antibodies and ADCs targeting ROR1 to exploit products covered by or incorporating the licensed intellectual property rights.
View on SEC.gov